Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

CAMP

CAMP4 Therapeutics Corp

Jan 21 • 04:00PM ET

4.50

+0.06 1.35 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-2.45	Insider Own	59.71%	Shs Outstand	46.88M	Perf Week	-25.74%
Market Cap	233.46M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	22.01%	Shs Float	20.90M	Perf Month	-27.54%
Enterprise Value	164.56M	PEG	-	EPS next Q	-0.30	Inst Own	34.29%	Short Float	3.58%	Perf Quarter	41.07%
Income	-53.40M	P/S	61.44	EPS this Y	83.27%	Inst Trans	9.52%	Short Ratio	4.53	Perf Half Y	169.46%
Sales	3.80M	P/B	3.60	EPS next Y	49.96%	ROA	-99.11%	Short Interest	0.75M	Perf YTD	-26.59%
Book/sh	1.25	P/C	3.10	EPS next 5Y	57.49%	ROE	-172.70%	52W High	7.30 -38.40%	Perf Year	-2.60%
Cash/sh	1.45	P/FCF	-	EPS past 3/5Y	-6.52% -	ROIC	-86.46%	52W Low	1.30 244.83%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	55.68%	Volatility	11.31% 9.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	43.31	EPS Y/Y TTM	5.51%	Oper. Margin	-1402.39%	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.83	Sales Y/Y TTM	759.14%	Profit Margin	-1404.47%	RSI (14)	33.24	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	9.83	EPS Q/Q	17.22%	SMA20	-22.75%	Beta	1.06	Target Price	8.75
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	-10.14%	Rel Volume	0.56	Prev Close	4.44
Employees	55	LT Debt/Eq	0.05	Earnings	Nov 06 AMC	SMA200	55.61%	Avg Volume	164.86K	Price	4.50
IPO	Oct 11, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-14.99% 83.66%	Trades		Volume	92,484	Change	1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-02-25	Initiated	Cantor Fitzgerald	Overweight	$7
Sep-16-25	Downgrade	JP Morgan	Overweight → Neutral
May-27-25	Initiated	Wedbush	Outperform	$8
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	Piper Sandler	Overweight	$18
Nov-05-24	Initiated	JP Morgan	Overweight	$23

Jan-16-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.00%
Jan-13-26 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 08:00AM	CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-19-25 06:01AM	Novo files for CagriSema approval; Merck and Pfizers trial win (BioPharma Dive)
07:10AM	Loading…
Dec-18-25 07:10AM	CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.90%
07:00AM	CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries (GlobeNewswire)
Dec-12-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.99%
Nov-14-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:05PM	CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.97%
Oct-14-25 02:09PM	3 Healthcare Companies Insiders Are Buying (MarketBeat) -6.63%
Oct-01-25 08:00AM	CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 (GlobeNewswire)
Sep-25-25 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know (Zacks) +7.53%
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks) -6.50%
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Sep-10-25 07:00AM	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders (GlobeNewswire) +40.20%
Aug-14-25 04:05PM	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.16% +7.74%
Jun-30-25 08:00AM	Sequans Appoints Jason W. Cohenour to Board of Directors (Newsfile)
May-16-25 06:00AM	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) +9.52%
May-13-25 04:05PM	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -7.92%
Apr-28-25 04:30PM	CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) -10.00% -5.15%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-27-25 04:05PM	CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -10.16%
Mar-18-25 08:00AM	CAMP4 Appoints Multiple Industry Veterans to its Board of Directors (GlobeNewswire)
Mar-04-25 05:24AM	CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey) -5.27%
Feb-06-25 08:00AM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.95%
Jan-13-25 08:00AM	CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 04:05PM	CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire) -8.08%
Dec-02-24 08:00AM	CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +5.85%
04:05PM	Loading…
Nov-21-24 04:05PM	CAMP4 Reports Third Quarter 2024 Financial Results (GlobeNewswire) +8.44% -6.40%
Oct-10-24 07:07PM	CAMP4 Announces Pricing of Initial Public Offering (GlobeNewswire)

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
5AM Partners VI, LLC	10% Owner	Sep 11 '25	Buy	1.53	2,941,176	4,499,999	2,941,176	Sep 15 08:12 PM
Polaris Management Co. VII, L.	10% Owner	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:59 PM
Nashat Amir	Director	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:48 PM
Maricich Yuri	Chief Medical Officer	Sep 11 '25	Buy	1.65	6,060	9,999	6,060	Sep 11 04:25 PM
Gold Kelly	Chief Financial Officer	Sep 11 '25	Buy	1.65	6,060	9,999	67,877	Sep 11 04:24 PM
Mandel-Brehm Josh	Chief Executive Officer	Sep 11 '25	Buy	1.65	6,060	9,999	278,417	Sep 11 04:23 PM
Young Richard A	Director	Sep 11 '25	Buy	1.65	15,151	24,999	170,010	Sep 11 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAMP

CAMP4 Therapeutics Corp

Upgrade your FINVIZ experience